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Badnam Science? The Spectre of the
‘Bad’ Name and the Politics of Stem
Cell Science in India
Aditya Bharadwaj
AUTHOR'S NOTE
The data in this article is drawn from a larger research project supported by the
European Research Council (ERC), Grant Number 313769. I am grateful to the special-
issue’s editors, Veena Das and Jacob Copeman, for their truly helpful and inspiring
comments. I also thank the three anonymous referees for their careful reading and
comments.
‘A rose by any other name would smell as sweet’
(William Shakespeare)
1 Badnam is a demolished name. Badnami is the soiled remnants, debris, of a name pulled
down. Names can implode with projectile ferocity, decimating immediate surroundings
and reverberating much further. The debris or detached broken remnants of a once ‘solid
name’  can  possess  the  shrapnel-like  intensity  that  revolves  around  a  spoiled  name.
However, proximity to the shards of an imploded name can be an opportunity as well as a
danger. We can say that the powerful gravitational force of an annihilated name can pull
within  its  ambit  proximate  and  distant  names  and  reputations,  with  unpredictable
consequences.
2 Names and naming, by their very nature, consecrate through a process of inscription and
encryption. The good and bad potential in a name is not always manifest. In this sense,
giving someone a name becomes an empty gift because the name is inherently empty to
the recipient but nevertheless imbued with an uncanny potential to engender, penetrate,
and define the entity so named. A good name is vulnerable, and a bad name has nothing
to lose except the hope to remake it. We can argue that, strictly speaking, bad+name (
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badnam) is not the loss of a name but rather an act of renaming or at the very least the
truncating of the signified. Derrida (1986) argues a name ‘appropriates itself violently,
harpoons, arraigns [arraisonne] what it seems to engender, penetrates, and paralyzes with
one stroke [coup] the recipient thus consecrated’ (Derrida in Ionescu 2011: 59). But in so
doing what does the name mask, or what aspects of a named entity escape naming? An
entity named is an entity (re)animated. This has consequences both short and long term.
And whilst a ‘bad’ name seemingly has ‘bad’ implications in the short run, badnam or
badnami can serve as a detour to a ‘good’ name (or reclaiming a once-good name, which
through the very act of reclamation stands transformed). I am neither arguing for nor
interested in seeing this as a process of resurrection: after all, badnami or bad publicity
can have  very  final,  fatal  consequences  for  certain  names,  and these  are  eventually
forgotten,  lost  in  time,  or  renamed and celebrated  (a  point  to  which I  will  return).
Drawing on French thinker Jacques Derrida’s philosophical oeuvre this article argues that
badnami does not necessarily sound the death knell  of  a name;  instead,  the inherent
vulnerability of a name makes difficult the task of predicting its social trajectory and
sketching  routes  and  detours  through  which  a  name  (re)establishes  a  ‘safe’  social
presence, a ‘safe’ social career. We can argue that this is because a name tries to represent
the unnameable aspect beyond the name itself. The article shows how a ‘good name’ is a
vulnerable,  slipping  mask concealing  a  potential  ‘bad name’  for  unnameable  entities
named ‘science’ and ‘stem cells.’ The movement from good to bad, from clean to soiled,
from famous  to  infamous  (badnam),  reveals  something  crucial  about  the  very  act  of
(re)naming. This movement does not so much rename good as bad or bad as good as if a
complete transition from one to the other is ever possible. Rather, renaming occurs when
shards of imploded good names and bad names come together to consolidate a new name.
This coming together conceals the symbiotic and semiotic co-production of good and bad
names.  Good  and  bad  names,  in  other  words,  are  admixtures  from deep  within  the
unnameable aspect of an entity struggling to manifest a new named aspect (i.e., pure good
and bad entities do not exist), and very often it is this mélange that slipping masks reveal.
3 The  article  opens  by  explicating  the  theoretical  and  conceptual  underpinning  and
proceeds  to  inspect  the  political  anatomy  of  stem  cells  in  India.  A  note  on  the
ethnographic  context  and  the  research  process  is  preceded  by  some  empirical
observations.  With  the  burgeoning  stem  cell  technologies  in  India  as  its  empirical
backdrop, the article focuses on a particular case of a stem cell facility in India offering
human embryonic  stem cell  therapies  as  a  site  to  explore  the  politics  underscoring
naming and name-calling in this promising but equally contentious scientific domain. In
the final analysis I am not seeking to generalize or draw conclusions for Indian stem cell
terrain  as  a  whole;  rather,  I  am utilizing  a  particular  case  to  show  how bad  name
reputational fears are understood in the mundane intricacies of the everyday.
 
Badnami: save the name, except the name
4 In his seminal essay, ‘Sauf le nom,’ Derrida meditates on the possibility of ‘sur-naming,’
supplemental  naming,  which  takes  the  place  of  the  name.  Unlike  a  family  name  in
English, surnom, sur-name in French, signifies a nickname. Ironically, a surname, family
name,  in a certain sense merely sur-names,  ‘nicknames,’  a  proper name found to be
incomplete,  lacking,  via  a  heritable  surname (see  Dutoit 1995).  Sur-name for  Derrida
names the unnameable because what is sur-named recedes, making the sur-name more
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than the name itself, and comes in the place of the name and thus on occasions even
replaces, substituting the name. Thomas Dutoit (1995) reminds us there is no adequate
translation of ‘Sauf le nom.’ The closest meaning in English would read ‘except the name.’
The literary ‘save’  as synonymous with ‘except’  allows ‘save the name’ to be read as
doubly articulate: as ‘except’ the name and to literally ‘save’ the name, the latter finding
rare and discreet mention in the text. However, the foregoing allows us to ask if sur-
naming is ‘except’ the name, whether sur-naming exception literally ‘saves’ the name
being  sur-named.  More  important,  for  the  purposes  of  the  argument  here,  it  is
worthwhile to explore whether bad+name comes to sur-name a name and in the very act
establishes a new presence ‘except’ the name, excluding the name. If so, perhaps it is
possible to imagine the receding, effacing, replaced name as ‘saved’ by the bad+sur+name.
The  (presumably  good)  name  being  sur-named  as  ‘bad’  then  makes  the  task  of
(re)establishing the original name rather difficult and unnameable. As Derrida puts it, ‘As
if it was necessary both to save the name and to save everything except the name…as if it
was necessary to lose the name in order to save what bears the name…’ (1995: 58). A name
names that which is beyond the name, the transcending truth that is other than the
name. In this respect the name is always lacking, and this lack, ‘except (save) the name,’
makes  naming a  necessary exercise.  The diversity  of  names,  new names,  old  names,
pseudonyms, and multiple (sur-)names circulate in a constellation that typifies neither
the name nor what is named but rather beyond, in a realm where the consecrated entity
remains unnameable or in a state where it is much more, [‘save/except’] the name. A ‘bad
sur-name’  is  then ‘except’  (save) the unnameable that is  not necessarily its  opposite,
‘good,’ but rather an unnameable, unknowable, unutterable entity that is ‘saved’ because
it cannot be named—an entity that can resurface to truncate the sur-name, replacing as
well as effacing the name and what it signifies. In this sense Derrida could be understood
as suggesting that ‘the name hidden in its potency possesses a power of manifestation and
occultation, of revelation and encrypting. What does it hide? Precisely the abyss that is
enclosed within it. To open a name is to find in it not something but rather something
like an abyss, the abyss as the thing in itself’ (2002: 213). A sur-name is the name inscribed
over a bottomless abyss, a name shaped by what it seeks to cover, hide, represent, and
utter. Name can be lacking because name fails to capture the essence of that which it
names, which in the final analysis remains unnameable and possessing abyss-like depth.
5 In India, badnami is not just opprobrium or defamation, but also a badge of honour, at
least in certain contexts. In this respect we can begin to piece together how the loss of a
name, its sur-naming, can be a generative process and the starting point of renaming a
set of practices that stabilize as ‘good.’ The valorisation of badnami or its willing embrace (
e.g., to embrace badnami or ignominy in love) is one such arena where loss helps gain a
reputation  of  another  kind  that  is  transient  and  always  tantalizingly  close  to
accomplishing normative stability.
6 A name, good or bad, becomes a mask that is difficult to detach from the person/entity to
whom it is attached. Following Derrida, the name, not the ‘unnameable’ person or entity,
becomes fused with the person or entity and seizes control of the person/entity with an
important  caveat:  the  context  and  everyday  contingency  can  potentially  mutate  to
conjure the signified to mean different things. That is, from deep within the ‘abyss’ the
unnameable can uncannily manifest and conjure a new sign.  In this respect,  badnami
simultaneously  can  be  a  cause  of  shame  and  social  opprobrium  as  well  as  an
understandable momentary affliction. Lyrics of an immensely popular Bollywood song, ‘
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Munni badnam hui darling tere liye’ (Munni goes infamous [loses her reputation/name] for
you o darling), are an unlikely but helpful lesson in understanding the badnami’s anatomy.
What we learn from Munni’s predicament is that badnami is a public event with very
public consequences. From Mira Bai (mystic poet circa 1498–1546) to Devdas (character
from 1917 Bengali novel by Sarat Chandra Chattopadhyay) to ignominious Munni, we see
a long and impressive genealogy of Indian people, fictional and real, embracing amorous
badnami. Paradoxically, bad+name in these examples asserts itself as both tolerable and
deplorable. For example, Munni’s situation obliquely references an invisible, untarnished
name slipping and soiling that is  public on account of  her amorous attachment to a
nameless (but sur-named) ‘darling.’ The temporality implicit in the name’s vulnerable
social  circulation  conceals  a  movement  from  the  private  realm  to  the  public,  from
invisible to visible,  and from implicit  to explicit.  The consequences,  whilst  gendered,
reveal the moral texture of a name that easily frays and disintegrates explicitly, visibly,
and publicly. The mask does not so much detach from the face but rather slips, revealing
in a moment of collective public gasp the frail contours of a nameless face acquiring a
new (bad sur-)name, a new mask. It is in the precise moment of grappling with the mask
one discovers the fragility of a name—the public disrobing and equally public enrobing of
a name gesture at the possibility of recovering one’s original name, mask, robe. But at the
same time, the collective gasp echoes a fearful reminder that any name can slip and soil,
becoming  something  other  than  what  it  signifies.  Above  all,  an  uncanny,  lurking
awareness takes hold, hinting and haunting from the unnameable, unknowable depths
concealed by a name, the possibility of a new nameable aspect emerging.
7 The foregoing is a cryptic conceptual plotline of events seemingly a world away from the
badnam streets invaded by ‘unsupervised,’ rebellious women like Mira and Munni and the
occasional ‘failed man,’ Devdas. This is a story of the burgeoning and high-stakes field of
stem cell science in India where a lone stakeholder clinician can be fighting to rescue his
or her reputation for fear of badnami and ignominy (to invoke one possible meaning) in
the  face  of  regulation—commonly  acknowledged  as  lax—and  the  rapidly  deepening
reputation of the field as a global site populated in equal measure by mavericks and
mavens.
 
Bad+name science: political anatomy of cells
8 In her ground-breaking book Good Science: The Ethical Choreography of Stem Cell  Research
(2013),  Charis  Thompson  describes  the  politics  underscoring  Proposition  71  and  the
California Stem Cell  Research and Cures Act.  Briefly,  this proposition was enacted by
California voters in 2004 to support stem cell research, most notably, embryonic stem cell
research, in the state. The California Institute for Regenerative Medicine (CIRM) is a state
agency brought into existence by Proposition 71. Funded by state-bond funds and backed
by taxpayers for three billion over ten years and at a time when public libraries and
schools across California were facing closure, the CIRM became a unique holding space for
hype/hope, promise/despair, risk/reward, and intractable diseases/promissory cures.
9 However, the promissory value of the CIRM and its ‘good name’ took a big hit when local
media began running stories  highlighting its  ‘insular’  and ‘insider-like’  way of  doing
business (Hiltzik 2014). The main area of contention was the CIRM’s former president,
Alan Trounson, who accepted a position on the board of directors of one of its highest-
profile  grantees,  Stem Cells,  Inc.,  on 7  July  2014,  seven days  after  leaving the  CIRM
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(Hiltzik 2014).  The  CIRM  promised  to  look  into  the  relationship  between  its  former
director and a high-profile grantee. Los Angeles Times reporter Michael Hiltzik wrote:
A well-connected company with questionable finances and a research proposal of
uncertain scientific validity has received favorable treatment from the CIRM. An
investigation of the relationship between the firm and the CIRM’s management was
placed in  the hands of  a  law firm inextricably  entwined with management  and
given an inappropriately narrow scope. The unanswered question burning a hole
through the CIRM’s credibility is whether Stem Cells, Inc. got its money because its
research  was  promising  or  because  it  knew  the  right  people. For  most  of  its
existence, the CIRM has been deeply hostile to outside scrutiny. The harvest is now
coming in.
10 It  seems  the  ‘good  name’  of  ‘good  science’  is  in  tatters.  The  once  ‘solid  name’  and
reputation of the CIRM and its director exploded with a shrapnel-like intensity around an
emerging ‘bad name.’ The unfolding scandal exposes the vulnerable underbelly of ‘good
name/good science.’  It  offers a fleeting glimpse at what ensues when science fails to
entwine ethics as per the norms of established choreography. This case shows not that
robust  scientific  scrutiny is  unforgiving and scrupulously  ethical  but  rather  that  the
quality  of  communication  and  circulation  within  a  local  environment  can  rapidly
precipitate a prefix switch and alter the very environment in which good and bad names
gestate (Bharadwaj 2014). This case also offers a peek into the unnameable manifesting
from behind a seemingly good and/or bad name. We can say a name not only remains
vulnerable, but also conceals an unspecified aspect that bodes forth demanding a new
(sur-)name.  The  paradox  at  the  heart  of  this  scandal  is  that  it  embodies  all  the
reputational fears bad science in global locales like India is believed to inflict on good
science.
11  The emergence of stem cells in India has long been in the making. I have analysed the
long  genealogy  of  developments  leading  up  to  the  birth  of  cellular  politics  in  India
elsewhere (Bhardwaj and Galsner 2009). Here I wish to outline ways in which state actors
and private stakeholders—most notably, scientists, clinicians, journalists, and academics
—make claims for regulation, relevance, and resolution. In so doing I wish to sketch out in
broad strokes how commentaries on what I am calling the political anatomy of stem cells
in India mirror politics of  naming and name-calling within this burgeoning scientific
terrain.
12 A great deal of policy-setting, journalistic, and academic ink is currently flowing on the
issue  of  stem  cell  technologies  in  India.  The  stated  objective  of  the  Department  of
Biotechnology (DBT), as per the eleventh five-year plan of the Indian government (2007–
2012),  was  to  make  India  globally  competitive  by  converting  the  country’s  diverse
biological resources into useable products supported by a strong bio-industry base with
an enhanced capability for market diffusion. The same goal is reinforced in the twelfth
five-year  plan  (2012–2017).  As  early  as  2005,  India’s  union  minister  for  science  and
technology proclaimed the government’s intention to strengthen stem cell research in
the  country  and support  companies  that  followed the Good Manufacturing  Practices
(GMPs)  per  international  guidelines;  in  this  way,  their  products  could  be  marketed
globally (Bharadwaj 2009).
13 The Indian stem cell landscape is seen as an uneven terrain where a range of maverick
and unethical activities dovetail scientific strides in a consensible direction. In the most
recent iteration of the National Guidelines for Stem Cell Research (2013), issued by the
Indian Council of Medical Research (ICMR) and the DBT, stem cells are described as not
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being part of standard care, and therefore no guidelines for therapy can be issued until
efficacy is proven. Under the new dispensation no stem cell therapies can be offered to
the patients except hematopoietic stem cells that are treated as a proven therapy. Stem
cells  can only be used in clinical  trials  after  due approval  from the Drug Controller
General  of  India  (DCGI).  In  tandem the DCGI  is  to  modify  Rule  21  of  the  Drugs  and
Cosmetics Act to include ‘stem cell and cell-based products’ as new drugs (DCGI 2013).
This means clinical trials involving stem cells will require a license from the DCGI. The
moves are seen as protecting the name of a promising and burgeoning field of stem cells
from mavericks and unscrupulous practitioners tarnishing the image of stem cell science
in India. However, these new developments are also being seen as a major hurdle in the
way of medical tourism due to proposed regulatory barriers and bad name reputational
fears (Jayaraman 2014).
14 The effort to cleanse India’s reputation globally has received further fillip ever since Mr.
Modi’s landmark victory in the Indian general elections in May 2014. The professed aim of
Mr. Modi, widely (and wildly) circulated in the media, is to turn India from a ‘scam state
to skill state.’  The renaming (and rebranding) of India is indeed ironic given that the
newly elected prime minister has struggled to cleanse his own bad name and past, as he is
commonly  held  accountable  by  this  opponents  for  the brutal  religious  violence  that
ripped through Gujarat state in India in 2002, when he was chief minister. However, by
renaming India as a good, honest place to do business and culture innovative ideas, the
new prime minister successfully creates new grounds for a renaming exercise that may
have  redemptive  consequences  for  his  own.  The  prime minister’s  flagship  initiative,
‘Make India,’ is a big step in this direction, soliciting foreign direct investment in 25 key
‘sectors’ that include biotechnology, pharmaceuticals, and a notable subset: stem cells. If
India is indeed a good place to do business, then the business of stem cells has to be
protected, and the name of India and the stem cell terrain as a whole needs to be shielded
from  bad-name  publicity,  or  badnami,  that  not  only  can  have  serious  reputational
consequences, but also result in a crisis of credibility with the potential to impact the
commercial  bottom line  and India’s  ability  to  attract  global  capital  inflows  (see  also
Bharadwaj 2009).
15 Within academic debates—most notably, social science commentaries—the key concerns
have  centred  around  issues  of  governance  vacuum,  potential  for  harm,  patient
recruitment and patient exploitation,  reputational  risks,  and therapeutic ambivalence
(Patra  and  Sleeboom-Faulkner 2009;  Salter 2008;  Sleeboom-Faulkner  &  Patra 2011,
Prasad 2015).  The  protagonists,  mainly  clinicians  and  scientists,  are  portrayed  as
breathing easily in a governance vacuum or as manipulating a range of uncertainties in
pursuit  of  reputation enhancement  (Salter 2008;  Sleeboom-Faulkner  &  Patra 2008).
Disgruntled patient voices are similarly co-opted to show that treatments are often no
more  than  loot mar (cheating)  in  the  ‘name  of  stem  cells’  (Sleeboom-Faulkner  and
Patra 2011). Specific clinics are singled out to generalize gratuitously how gullible and
desperate patients are in danger of being recruited and lured into stem cell treatments.
Instances  where  patients  report  positive  treatment  outcomes,  ambivalence,  and
uncertainties are shown to be unresolved. In other words, patients in these accounts are
analysed  and  ‘named’  as  vulnerable,  hopeful,  ambivalent,  duped,  exploited,  or  a
combination thereof.
16 At  one  level  these  conclusions  are  underwhelming  for  three  key  reasons.  First,
generalizations based on specific clinics and their collaborators tell us very little about
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the  scientific  domain as  a  whole,  however  contested.  Second,  any person or  patient
struggling with a degenerative disorder, whether static or progressive, is highly likely to
occupy  an  ambivalent  space.  Even  when  the  therapy  is  seemingly  working  it  is
understandable to want more improvement, greater resolution, and to ‘hope’ for more.
This  cannot  be  captured to  deduce that  stem cell  interpolations  are  not  working as
imagined or  promised.  Stem cells  aside,  even in  the adjudicated terrain  of  so-called
mainstream biomedical therapies held to be scientifically validated and purportedly safe,
a  straightforward  resolution  or  outcome  is  seldom  available.  Third,  much  of  this
scholarship deploys the vocabulary of ‘ethics,’ ‘governance,’ ‘experimental,’ and ‘(un)safe’
as  fully formed and as  taken-for-granted categories.  Like the notion of  name in this
article, each of these concepts should be vivisected to reveal the cultural complexities
animating their named presence in our professional lexicon. Instead, most social science
accounts, whether unwittingly or wilfully, end up contributing to the production of a
badnam ‘geography of blame.’
17 A critical understanding of the stem cell terrain in India needs a more substantiated and
corroborated  understanding  of  the  field.  But  more  important,  it  demands  that  the
researcher abandon his or her precarious perch on the fence and get down to the difficult
analytical task of revealing how a therapy and its workings are constructed, understood,
and eventually assimilated.  Very often the objective fence-sitting risks looking like a
tactical move to distance from a potential bad sur-name in the making. In this scene of
sophisticated academic name-calling, academic reputations are also at stake: being too
close or too distant from the object of study can further imbricate the value-laden terrain
of social science positioning and spectating. Social scientists, like the natural scientists
and clinicians they ‘study,’  are in the business of making a name for themselves and
establishing a reputation in their chosen fields of expertise. In these accounts we find
that  rather  than understanding the  anatomy of  a  bad name in  the  making,  not  too
dissimilarly from their natural-science and journalistic counterparts, social scientists are
either actively distancing themselves from a scene of badnami or constructing one by
deploying theoretical and analytical tools that produce an illusion of objective distance
from a purportedly unethical ‘scene’ under scrutiny. In my own work, this has been a
source of much reflection and critical self-appraisal, a source of constant questioning of
my tools, techniques, and ability to understand and explain notions of therapy, efficacy,
harm,  cure,  disease,  and  the  politics  underscoring  these  troubled  relationships  (e.g.,
Bharadwaj 2013).  However,  new  emerging  insights  are  instigating  refreshing  new
perspectives  on  the  vexed  question  of  stem  cell  governance  and  asking  pertinent
questions such as ‘what does the effort to debate and govern stem cell therapy conceal as
well as reveal about India’s engagement with biomedicine?’ (Tiwari & Ramana 2014: 415).
At this juncture it seems very likely that as the conversation evolves the terrain will move
towards a more nuanced and reflexive engagement in naming the stem cell terrain, in
keeping with its dynamic nature.
 
The ethnographic backdrop
18 My ethnographic  focus  is  a  small  clinical  facility  in  New Delhi,  a  site  where  I  have
conducted stem cell fieldwork since 2002. The small clinical facility is an outlier to the
extent that it is a marginal player in the high-stakes field of stem cell science in India and
around the globe. However, the clinic offers a compelling illustration of the politics of
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making bad and good names and forms part of a multi-sited ethnographic project. In this
article I  am seeking to trace the metaphors of badnam and badnami through multiple
terrains to piece together a fragment seemingly scattered in disparate domains ranging
from local and global bio-scientific controversies to multi-media reports, which Marcus
(1995)  in  his  original  formulation  describes  as  one  of  the  most  important  sites  for
cultivating a fully formed multi-sited ethnographic practice, to everyday ethnographic
encounters  and  conversations  in  mundane  settings.  Largely,  this  article  draws  on
intensive and longitudinal participant observation in the previously mentioned clinical
facility and on fieldwork in other parts of India as well as local and global media reports,
along with interviews  and daily  conversations  with the  clinic  director.  This  ongoing
research is examining stem cell technologies in India and the contested nature of stem
cell science in the ethical as well as regulatory landscape in India. The very act of naming
and separating good science from bad science appears to drive these developments. A
multiplicity of actors—from the Indian state to private stem cell start-ups as well as local
and global patients in search of stem cell therapies—have come to have a vested interest
in the ‘correct and fair naming’ of the Indian stem cell terrain. The global bio-scientific
adjudications and pronouncements on what constitutes good-name science have only
exacerbated the contest  on naming the unnameable  depths  of  scientific  and cellular
therapeutic potential (Bharadwaj 2013a, 2013c). Interactions with the growing number of
Indian and foreign-treatment seekers are yielding insights into the contingent nature of
healing, agency, and wider reaction to hESC-based therapies.  Treatment seekers from
different parts of the world reported that the professional and biomedical response in
their countries of origin was to (sur-)name them as gullible dupes being manipulated by
guileful  stem cell  mavericks  in  India.  The  good/gullible  and  bad/guileful  naming  of
players in this infinitely complex field of global travel for stem cell therapies reveals just
another layer in the (re)naming practices haunting the emerging stem cell  terrain in
India (see Bharadwaj 2012, 2013c).
19 In this article all names are kept anonymous to preserve confidentiality, as per the ethical
protocols at the Graduate Institute of International and Development Studies, Geneva,
and the European FP7 framework guidelines.  However,  where interviewees  expressly
asked  to  be  identified by  their  first  names  no  anonymity  was  attempted.  Also,  in
accordance  with  prevailing  institutional  and  European  Commission  FP7  framework
ethical  injunctions,  I  have  attempted to  keep the  identity  of  the  clinic  or  the  clinic
director  anonymous.  However,  I  am well  aware  I  may  not  succeed,  as  both  feature
prominently in global-media debates and regulatory, as well as scientific, public spheres
(see Bharadwaj & Glasner 2009).  The very act  of  sur-naming research-participant and
related entities such as clinic names creates ironic but creative solutions involving names
and what they are held to reveal, mask, and make explicit if uttered and made unsafe
through the modality of naming. The bureaucratic logic that seeks to ‘save the name’ via
pseudonym sur-naming echoes what Das describes (2015)  as a kavacha (shield name),
which protects a child from ghosts, who are cunningly deluded into thinking the child’s
public name is the real name (which is only known to the parents). The bureaucratic
shielding of  the research subject  from potential  harmful  exposure creates  conditions
where only the researcher knows the real, asli,  name (see Saria 2015). In other words,
everything ‘except’ the name becomes nameable in order to ‘save the name.’
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Badnam science
20 My  ongoing  conversation  with  the  clinic  director  began  in  2002.  Throughout  my
interactions she has shown reflexive awareness about the source of criticism haunting
her clinical work, which is in danger should the Indian lawmakers ratify the proposed
legislation demanding DCGI-approved clinical trials for stem cell therapies. In the first
phase of my interactions (2002–2005) we discussed the promise of stem cells and the
challenges in proving safety and efficacy. This was at a time when human embryonic stem
cells were being ‘named’ globally as the most potent source of regeneration. The second
phase (2005–2010) moved the conversation towards clinical and therapeutic work; this
was also when international criticism and peer outrage began to gain prominence and
become consolidated in the public domain in India and beyond. The name-calling from
peers and journalists alike made her reflect and focus closely on her location in India and
the potential prejudice in the Euro-American terrain towards biomedical breakthroughs
in distant parts of the globe (e.g., Guardian 2005). For example, in 2008 a team of British
scientists discovered antibiotic-resistant bacteria and proceeded to name it New Delhi
Metallo-beta-lactamase-1 (NDM-1). By about 2010, the naming controversy had spread to
India and was heavily criticized by the Indian state and the scientific community alike.
The  NDM-1  team leader,  Dr.  Walsh,  advised  people  to  ‘think  long  and  hard’  before
undergoing  treatment  in  Indian  hospitals  (Narayan 2010).  As  this  controversy  was
unfolding the clinic director saw this as just another example of bad-name politics on a
global scale:
You take the issue of the super bug they have accused, they have done a research
and they have published in the Lancet. Now I will question the Lancet editor as to
why he  allowed that  to  happen if  he  is  supposed  to  be  the  editor  of  the  most
reputable peer-reviewed journal, how did he allow an article with 35 patients to be
published? They are saying there is a new Delhi super bug, they named it after my
city, and that 35 patients came in and got the super bug, so don’t go to India for
surgery; how can you know that? Did you have proof that this patient did not carry
this bug into India and went back with it? Number two, how can you pass such a
statement in a journal, then what do you say, you say that this a Euro-American
kind of bias, this is the biggest proof I think of as to how they don’t want anyone
else’s medical, scientific breakthroughs or services to flourish.
21 The naming and name-calling  in  this  controversy  was unprecedented,  as  the  Lancet,
which  published  the  breakthrough,  openly  accused  the  Indian  government  of
‘suppressing’ the truth about the presence of drug-resistant bacteria in Delhi’s public
water system (Indian Express 2011). The controversy, however, only reinforced the fear of
well-orchestrated badnami and its ability to truncate names and indelibly attach itself to
people and places.
22 The third and ongoing phase of my conversation with the clinic director (2010–2015)
hybridized the focus of the earlier phases, as the clinic director began reflecting on a
continued failure to communicate her work to her peers and her location in a constructed
‘geography of blame.’ She felt both factors were offering her detractors the ammunition
to tarnish her reputation and name. For example, since 2011 she has believed that the
media name-calling has resulted in an inability to publish papers in scientific journals.
She remains hopeful that publishing her data will lead to a new sur-name, quite possibly a
good cleansed name, vindicating her work thus far. When asked in 2013 whether she
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thought ignorance and the fear of the unknown were brought on by a lack of published
data, she concurred: ‘Absolutely! Come on, Third World country, India, stem cells, we
can’t even handle our traffic, I understand, I get that, I get that, they are sceptical. At the
same time I know my thing is working.’ In her assessment, publishing data was only part
of the solution. The location of her work was also largely badnam. I often probed deeper
when she referenced an unknown ‘they’ as the source of opprobrium and bad name:
AB: Who are the ‘they’?
CD: ‘They,’ let’s say CNN, for example, their choice of patients, choice of words, but
they give me a one-hour documentary, and then they have the cheek to come to my
country, my city, and my everything and have an entire discussion on my work
without inviting me, I mean that shows me I am important, that’s wonderful! Let
them criticize me.
23 In  2012,  CNN  had  caused  a  small  ripple  with  their  documentary  on  her  stem  cell
therapies. I had a ringside view to the five days of shooting at the clinic and the series of
interviews with the clinic director as well as many of the in-patients (I later learned they
interviewed patients in the US over several months). However, many of these patients did
not make it to the final cut, and in the words of the clinic director, ‘they chose to speak to
a patient who had improved but could not speak for himself, with divorcing parents who
were not speaking to each other.’ The documentary had deployed the tell-tale signs of an
Orientalizing trope and some glaring factual inaccuracies. For example, the voice-over
describes how disabled patients, in this ‘less than luxurious facility,’ were forced to use
toilets down the corridor. However, all  patient rooms have attached disabled-friendly
bathrooms. The clinic director later quipped that truthful narrative would have done
little for the bad-name science drama CNN was seeking to relay to the world.
24 On 14 August 2012 CNN screened the documentary in the India International Centre in
New Delhi. The screening was for an invited audience, but the clinic director was not
invited. However, as she later recalled, ‘unfortunately I was there.’
AB: How did you get there?
CD: I was there for another programme.
AB: What programme?
CD: A birthday party. (Laughs)
CD: People recognized me in the toilet: ‘Hey, your program is up there.’ I said, ‘Hey,
let me go up there!’
AB: You’re joking, you’re making this up?
CD: No I am not, I never joke, and I never speak an untruth. I walked in, I sat down,
and they were towards the end of the screening, and then they got up and asked,
Yes, are there any comments, so I stood up and said, ‘As this programme is about
me and I have not been invited and I am busy, I need to say a few words,’ and I
spoke a few words to the audience.
AB: And what was the reaction?
CD: The audience thought it was a very one-sided program and they [CNN] were out
to get me. In fact I got few patients from that audience thereafter! And then the
CNN chief I think was very kind to ask whether he could come back again, and I said
you’re most welcome anytime, [but] speak the truth!
25 The growing media interest in her work and the very public naming and renaming of the
clinic director had become an established trend by 2012. If anything the name-calling and
trial by media was getting shrill. The Guardian story that set the ball rolling in 2005 cited
experts who unanimously concluded that her stem cell story was ‘highly implausible and
frankly  downright  dangerous.  If  the  Indian  government  wants  to  promote  stem cell
research, then it needs to seriously look at regulation of these doctors and if necessary
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close them down.’ Similarly, a host of media reports alluded to the clinic director as a
‘dangerous  maverick’  (see  Sky  News 2006,  2007;  Telegraph 2007,  2008;  Fitzpatrick  &
Griffin 2012). The conclusion was unanimous that such maverick clinicians were bringing
the science of stem cell into disrepute and giving scientists everywhere a bad name. The
clinic director, however, has repeatedly hit back, arguing that her name is being dragged
through the  mud and  despite  dramatic  reversals  in  several  patients,  she  is  unfairly
ostracized and her name wilfully maligned. Asked whether she felt largely discredited she
responded, ‘No, I never feel discredited. My patients give me all the credit. I don’t need
any outside stamp of approval for feeling good about my work.’
26 Many  clinicians  and  stem  cell  practitioners  around  India  see  patients  and  patient
testimonies as a natural corrective. A disgruntled or harmed patient can result in serious
badnami. A negative testimonial also instils a fear of losing patients as well as losing face.
The consequences are both reputational and financial. Bad+name is not good for business.
For  example,  Forbes magazine  articulated  these  bad-name  reputational  fears  most
explicitly in a 2013 article, when it claimed that ‘fearing that unscrupulous use may hijack
this  promising  field  [stem  cells  in  India],  stakeholders  are  racing  to  regulate  its
applications.’ The main fear articulated in the news piece was that of reputation, a fear of
losing credibility. By citing several ‘expert’ testimonials, the piece cautions how ‘between
the huge unmet human need for treatment of incurable diseases and the hype around the
possibilities  of  these  therapies  on  one  side,  and the  opportunistic  and unscrupulous
physicians exploiting the situation on the other, good science [emphasis added] struggles
to move forward…’ (Forbes 2013).
27 A closer reading of the concerns in this article reveals the financial potential of stem cell
markets globally and the Indian potential stalked by concerns about poor reputation. The
article (guess)timates the global potential as being around 1.2 billion in 2012 and growing
at 30% to reach 16 billion by 2017, 600 million of which would be the Indian-market
segment.  The  article  valorises  ‘experts’  it  cites  as  ‘rooted  in  science’  against  the
unscrupulous elements  that  by implication only feign scientific  know-how.  Making a
strong pitch for the commercial potential of stem cells,  the article cites Minger, who
moved from King’s College London to GE Healthcare, as ‘he thought the time was right for
commercialization,’ arguing that the international marketplace needs regulation so that
‘the reputation of regenerative medicine is not compromised.’ The vulnerable (sur-)name
of an unnameable entity, ‘stem cell science,’ continues to oscillate between the good- and
bad-named protagonists. What journalistic ventures such as the Forbes article discussed
previously and the larger scientific establishment fail to capture in any meaningful way is
that names are not just vulnerable, but also seldom permanent. Reputational fears of
good  going  bad  or  bad  going  good  remain  an  inadequate  possibility  because  the
unnameable  aspect  of  an  entity  or  person  is  adept  at  manifesting  the  unutterable
concealed by a (sur-)name.
 
A bad name by another name
It’s centrifuged blood: that’s all. They are drawing blood from patients, centrifuging
it in a lab in Bangalore for six to seven thousand rupees and injecting it back into
patients for two lakh rupees. They do this, and stem cells get badnam. If this doesn’t
stop, stem cells will become a badnam science, you know? People simply don’t care;
it’s just another get rich quick scheme, never mind the damage to the reputation,
never mind the badnami.
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28 It was just another Wednesday afternoon as the clinic director and I sipped tea in her
office. The outpatient rush had subsided, and we discussed the complexities of the Indian
stem  cell  terrain.  Her  criticism  of  ‘rogue’  stem  cell  clinics  in  India  was  ironically
paraphrasing  castigations  she  routinely  received  in  the  local  and  global  media.  The
outburst  was  also  ironic,  as  the  revised ICMR-DBT (2013)  guidelines  had singled out
hematopoietic stem cells as permissible. It was clear from the guidelines that ‘minimal
manipulation’ of stem cells via centrifuging, so long as under aseptic, GMP and GLP (good
laboratory  practice)  conditions,  did  not  need  Institutional  Committee  for  Stem  Cell
Research oversight nor DCGI approval. The bureaucratic and bio-scientific renaming of
centrifuged blood as stem cells was another fascinating development underscoring the
emergence of politics of (re)naming biogenetic artefacts. After all, clinical use of entities
such as bone marrow is decades old and yet renaming bone marrow as stem cells recasts
something old and familiar into a new and strange entity needing robust governance.
29 That a range of mavericks and mavens populate the stem cell terrain in India is beyond
dispute. However, local and global media hyperbolae often paint the Indian terrain as
uniformly  maverick.  This  deepening  badnami is  cause  for  much  worry,  as  several
clinicians working on the forefront of stem cell therapies in India resist standardized
‘good  science’  prescriptions  emanating  from  the  ‘West’  (Bharadwaj 2013a,  2013b).
Ironically this resistance only reproduces tropic templates of ‘good and bad name science’
in a rapidly globalizing biotechnology. In other words, in this global scene any entity can
acquire a  bad name:  the science of  stem cells  (a  fear  routinely invoked by ‘Western
experts’),  individual  clinicians  (in  India  and  beyond),  and  cellular  form  itself  (as
inherently  dangerous).  At  every  level,  names  and  reputations  appear  vulnerable,
precariously close to going bad.
30 The everyday clinical encounters with stem cells in a reputational and bad-name vacuum
are far from straightforward. For example, as noted elsewhere (Bharadwaj 2013b), on one
of my regular visits to the clinic I witnessed a chronic spinal-cord-injury patient move his
toes and lift both his legs. The patient had moved his legs for the first time in fifteen
years, a dramatic moment for him and the clinic director. The clinic director appeared
vindicated, as if the patient, by moving his legs, had validated the therapeutic efficacy of
stem cells. Her excitement was tempered by the fact that this breakthrough would count
for nothing. Resigned but equally elated she quipped, ‘This is headline news; if this were
happening in America or Europe, forget lifting his leg. Even if he were moving his toes,
they would be hailing it as a breakthrough of the century.’ Smiling, she continued, ‘But
wrong place. It is not meant to be happening here, right?’ The isolation and ostracism of a
bad name made it possible for her to imagine the likely outcome and quietly accept it. It
is as if  a bad name renders worthless all  achievements; name and place conflate and
conspire to produce a favourable outcome with an unfavourable name. It is interesting to
note that many patients absorb the stigma of badnam science. It is as if the very act of
embracing a therapeutic modality embedded in the badnam science renders them gullible,
desperate, and duped. That is to say badnami comes to attach itself to a patient’s body and
erases the individual to an extent to produce a cohort that has lost all sense of judgment,
reasoning, and the will to exercise caution (Bharadwaj 2013b). Despite the long, tireless
history of researching stem cells and clinical facilities around the globe and in India,
informal participation and patient-support networks are similarly erased from scientific
and journalistic assessments (Bharadwaj 2013b). The surrender of reason and surrender
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of one’s corporeality is conflated. The bad-name science is bestowed with dark powers
that can ensnare while incanting a state of collective bad faith.
31 It is crucial to understand that badnami is a localized event that can reverberate much
further. In the present case, aspersions of badnam science are localized within a scientific
polity that is  ‘consensually constructed by scientists  and implemented from within a
specific view of science that sees in its putative modality all the necessary conditions to
normatively support, ideologically discipline, and structurally contain the experiment’
(Bharadwaj 2013c: 86). The global politics of science see this context as fundamental to
cordoning off adjudicated spaces in which only a consensible rule ordained ‘good’ name
science could thrive. The notion of ethics is as standardized as the fantasy body of a good-
name science that can be globalized cross-culturally to mean the same thing. However, on
a number of  occasions through the course of  my daily  conversations with the clinic
director I learned that ethics were not so much variable or in some essentialist sense
contingent or relative to particular cultures but rather universal in ways that
bureaucratized ethics embedded in bioethical discourse couldn’t possibly accommodate.
Through the course of our conversations over the years the clinic director has repeatedly
maintained how ‘it’s not that I am unethical; I am perfectly ethical, but my ethical work is
seldom recognized as  such.’  And yet,  I  could  not  understand the  resistance  towards
standardized ethical protocols and peer-endorsed practice that would have let the clinic
off the hook without the attendant inconvenience of acquiring a bad name. However, one
winter evening in 2014, a chance conversation with the director offered an interesting
peek into the fascinating world of stem cell science purportedly going badnam when she
said:
We never  opted for  a  clinical  trial  because we are  against  giving placebos.  The
patient is the control because there is chronicity, and it is not fair to treat a patient
with  a  placebo,  especially  if  an  ALS  [Amyotrophic  lateral  sclerosis]  patient  is
coming to you who is going down every day. The institutional ethics committee
[made the] decision a very long time ago that there [would] be no placebo, as it is
against our ethics; we can’t stand back and watch an ALS or motor-neuron disease
patient rapidly worsen and die; it is against our ethics.
32 At first I understood this outburst as a pursuit of ‘local good’ circumscribed by contingent
ethics that are produced in relation to sensibilities populating the everyday engagement
with life. It seemed that from the ivory tower of big, baroque science, badnam-science
interpolations into human biology appear dangerous, destructive, and unruly. However, a
closer reading reveals a wilful and willing embrace of badnami. The ethics of good-name
science is easy to accomplish, but the daily struggles of terminal and incurable patients
made it impossible for the clinic to stage-manage its good name.
33 I have followed ALS patients since 2012 and am very aware of how viciously the disease
attacks  stem  cell  insertions.  Constantly  beating  back  a  progressive  and  aggressive
condition is the only viable recourse. I met Warner (pseudonym) on his first-ever visit to
the clinic in May 2013. In Germany, where he was first diagnosed in early 2013 with ALS,
he was given fewer than three months to live.  A qualified surgeon who understands
biomedical prognostications, he looked for alternatives to fight the rapid progression of
ALS.  A  colleague  who  had  patients  return  to  Germany  after  successful  stem  cell
treatments in the clinical  facility in New Delhi suggested he try embryonic stem cell
treatment.
34 I first met Warner when in the clinic director’s consultation room. He was trembling, and
his hands and arms were shaking with festiculations.  The quivering skin and muscle
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spasms were incessant, and his speech was slow and on occasions muffled. Through the
course of the treatment at the clinic I witnessed his body stabilise to the point where one
had to peer closely at his skin to find spasmodic activity such as continuous twitching. By
the time he returned,  Warner was very stable,  felt  immensely energetic,  and walked
unassisted.
35 In May 2014, exactly a year after his first treatment, I flew to Berlin to meet him. It was a
sunny  May  morning  as  I  rang  the  doorbell  of  his  suburban  home  ensconced  in  a
meticulously planted garden. Much to my surprise, he answered the door and ushered me
into the front room where his in-laws together with his wife greeted me with homemade
cake and tea. Warner updated me on his progress. He was continuing to get stronger and
could even work part time. And since the debilitating condition fought back his recovery
narrative was punctuated by stories of setbacks and extreme elation as his body fought
back.  He  shared  his  ‘peak  flow’  graph  that  meticulously  tracked  his  daily  progress
through the months of March, April, and May. The upward trajectory of his progress was
heartening. A little later that evening we all left his home and walked two blocks to a
neighbourhood restaurant for dinner. The whole evening was spent talking and laughing
as  Warner  enjoyed  his  food  and  a  few beers—not  once  did  he  balk  or  complain  of
exhaustion. A little later that year Warner returned to Delhi for his ‘top-up dose,’ and
after a few months of sustained treatment he returned in early 2015. He often told me
how he knows when it is time to go to India for a top-up and likened his daily struggle
with ALS as a battle where he needs to reinforce his defences with embryonic stem cells.
When asked whether he was among the lucky few who survive ALS with little or minimal
medical treatment, Warner confronted me with accumulating evidence that showed a
clear correlation between the time lapsed since stem cell insertions and his worsening
condition as well as a subsequent pick up in progress after stem cell interpolations. He
often says he doesn’t need to convince anyone; he knew he was getting better but had to
go on fighting.
36 As  many  millions  around  the  globe  perish  each  year  awaiting  ethically  produced
translational research, the reputational fears of good-name science barely conceal the
‘ethical violence’ that does little to tarnish its name. It takes a giant such as the CRIM to
veer off the ethical track for a bad name to become a haunting presence. However, in the
case of the Indian clinic, and bad (sur-)named science, an unnameable good appears to be
gestating  in  prolonging  ALS-afflicted  lives.  Whether  it  will  precipitate  a  (sur-)name
change is another matter altogether. But, as in the case of the CRIM, the vulnerable name
conceals an unspecified aspect that comes forth demanding a new (sur-)name.
 
Conclusion
37 A bad name is a sur-name, that is, except/save an unnameable, unspecified aspect that
survives and resurrects to truncate what a sur-name, good or bad, can mean in a given
context. The (sur)names are uncanny and enchantment par excellence. They can trick
and dissimulate (Das 2015); precipitate contests overs real/asli and unreal/nakli names
(Saria 2015) or, as in this case, render names impermanently (sur-)named as bad or good.
The  negative  theology  implicit  in  Derrida’s  argument  makes  one  confront  the  ‘open
texture  of  a  name,’  that  is,  a  multiplicity  of  names  engendering  a  multiplicity  of
possibilities, which Das expertly describes in this collection. For Derrida, God is the name
of a ‘bottomless collapse,’ of ‘an endless desertification of language’ (1995: 55–56). The
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‘referential transcendence of language,’ according to Derrida, is to say God is beyond his
images, beyond the idol, or beyond what is said, seen, or known of him. Just as negative
theology  ‘refuses,’  ‘denies,’  and ‘rejects’  all  the  ‘inadequate  attributions’  (1995: 69),  a
name, good or bad, remains at best an ‘inadequate attribution.’  A negative procedure
allows  us  to  grapple  with everything  except  the  name that  keeps  the  possibility  of
renaming safe and a procedure for saving the name ever present. In other words, good or
bad names exist, ‘save/except’ the unnameable aspects beyond the name. This unique
quality  inhered  in  a  name  leaves  open  ended  the  possibility  of  canny  and  uncanny
manifestations from beyond the name to impact and truncate a name.
38 In India it is widely recognized that the world’s second and India’s first IVF baby was born
sixty-seven days after the birth of Louise Brown, on 25 July 1978. On 3 October 1978, Dr.
Subhas Mukherjee announced the birth of Durga in Calcutta. Dr. Mukherjee is credited
with many firsts in the world of reproductive and infertility medicine, including the use
of gonadotropins for ovarian stimulation, a transvaginal route for harvesting oocytes,
and the freezing and thawing of human embryos before transferring them to the uterus.
Although he published a short note on his work in the Indian Journal of Cryogenics,  his
claim was largely discredited. Deprived of any opportunity to pursue his research, public
humiliation and ridicule from his peers eventually resulted in Mukherjee taking his own
life in 1981. The badnam ‘quack’ was to remain unrecognized until the late 1990s, when his
diaries,  papers,  and  research  data  were  resurrected.  The  circumstances  leading  to
Mukherjee’s  suicide  and  the  politics  behind  his  subsequent  reinstatement  as  the
‘scientific father’  of  India’s  first  and the world’s second ‘test-tube baby’  are analysed
elsewhere (Bharadwaj 2002). Here I remind myself that bad name and badnami can have
dangerous consequences. Mukerjee’s name is now purified to the extent that he is hailed,
by the very establishment that drove him to suicide, as the scientific father of the first
test-tube  baby  in  India  and  the  second  in  the  world.  Names  can  be  restored,  but
restoration is not the same as re-establishing the previous one. Salvaging a bad name
entails renaming. Nothing is salvaged, reclaimed, or regained. The new name is a new
start, a precarious journey of a vulnerable new name.
39 The story of stem cells in India is similarly replete with ironies. The ‘pro-cure’ rhetoric of
‘good (sur-)named/good science’ that enabled the CIRM in the United States to come into
existence is seemingly bearing fruit in distant ‘bad+sur+named’ Indian clinics, where stem
cell  therapies  are  thriving and in some quarters  producing results.  Another  irony is
centred on  the  need  for  external  validation  and  credibility,  as  shown  by  the  clinic
director cited previously as saying, ‘My patients give me all the credit. I don’t need any
outside stamp of approval.’ The global-media reports are replete with expert testimonials
either  condemning  the  clinic  or  doubting  the  reported  outcomes  whilst  grudgingly
reporting breakthroughs that appear to be making a difference.
40 The  Forbes report  discussed  previously  had  similarly  criticized  the  clinic  by  stating
‘personal testimonies are not scientific data, and this distinction needs to be made when
reporting these stories [of treatment breakthroughs] […] some clinics [‘naming’ the clinic
and the clinic director] are beginning to understand this…’ (2013). What the Forbes report
and several other journalistic accounts failed to grasp was that the clinic had steadfastly
opposed scientific publications in peer-reviewed journals on legal advice to protect its
pending patent application, a somewhat unusual but not uncommon practice across the
globe  (see  Bharadwaj 2013a).  This  refusal,  however,  further  cemented  the  bad-name
credentials  of  the  clinic,  and  many  scientific  and  journalistic  quarters  wilfully
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(mis)understood  this  as  further  evidence  of  the  clinic’s  suspect  and  poor  scientific
practice. From 2013 to 2014, the clinic was granted 65 patents around the globe. As if on
cue, the clinic director began submitting several articles detailing everything from the
science behind the stem cell interpolations to treatment protocol and systematic data on
treatment  outcomes  broken  down  by  terminally  progressive  and  incurable  static
disorders for peer review in international  scientific journals.  At  last  count seventeen
articles have appeared in peer-reviewed journals. The bold and radical departure from a
peer-endorsed modality of stem cell procurement, culture, and administration has now
become validated, but the clinic director is still waiting for a verdict on her attempt to
cross an important passage point, peer-reviewed journal articles, and whether this will
result in a landmark scientific publication. As these articles circulate and are scrutinized
the prefix may switch from bad to good. And it is not long before the curtain goes up on
the penultimate scene in this bad-name drama.
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ABSTRACTS
The range of the implicit meanings of badnam (bad name) stop short of unpacking the complexity
underscoring the implied soiling and spoiling of ‘name’: the crucible of reputation, honour, and
dignity. What happens when diverse stakeholders working in the burgeoning and high-stakes
field of stem cell science in India fear badnami, ignominy (to invoke one possible meaning), in the
context of a regulatory flux and fears of rapidly deepening reputation of the field as a maverick
site for stem cell research and clinical application? Drawing on longitudinal research mapping
the stem cell technology terrain in India and the changing fortunes of a small clinical facility,
this article shows how the spectre of ‘spoilt name’ (or badnami) haunts professional narratives
and  how  scientific  validation,  national  honour,  economic  viability,  therapeutic  efficacy,  and
safety come to reside in the ‘name.’ The article conceptualizes ‘name’ as inherently vulnerable
and examines its threatened status to highlight the unnameable, unspecified aspect that survives
demanding a new name despite the ethics and politics implicit in naming and ‘name-calling.’
INDEX
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